{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-214102","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2021-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.105171+00:00","generated_at":"2026-06-30T05:46:22.215875+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"IMARA files July 2021 corporate presentation on hemoglobin disorder pipeline","bullets":["Filed a corporate slide presentation as Exhibit 99.1 under Item 8.01.","Presentation titled 'Advancing Novel Treatments for Hemoglobin Disorders' dated July 2021.","No financial results, guidance, or material operational updates provided.","Routine disclosure of materials used in investor meetings; no new events announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-214102","json":"https://secwatch.observer/filing/0001193125-21-214102.json","markdown":"https://secwatch.observer/filing/0001193125-21-214102.md","text":"https://secwatch.observer/filing/0001193125-21-214102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/0001193125-21-214102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312521214102/d150922d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T05:46:22.215875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}